Fig. 5: BI-4020 with anti-EGFR antibody overcomes brigatinib-resistant compound mutants in vivo. | npj Precision Oncology

Fig. 5: BI-4020 with anti-EGFR antibody overcomes brigatinib-resistant compound mutants in vivo.

From: A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer

Fig. 5

a PC9-del19/T790M/C797S/L718M mutant cells were subcutaneously injected into nude mice, and treated with the indicated doses of panitumumab, BI-4020, or BI-4020 and panitumumab combination for 16 days. Average tumor volume was plotted as mean ± SD (n = 6). b Average body weight was presented as mean ± SD.

Back to article page